Administration of thiazolidinediones for neuroprotection in ischemic stroke: a pre-clinical systematic review.
Thiazolidinediones (TZDs) may prevent or attenuate CNS injury arising from an ischemic event. We performed meta-analysis of experimental studies in which a TZD (either rosiglitazone or pioglitazone) was administered in a rodent model of focal or global cerebral ischemia. Infarct volume was the primary endpoint for analysis of drug efficacy, and neurological outcome was also assessed. We identified 31 studies through the use of PubMed and Embase, 22 of which met our pre-specified inclusion criteria and were analyzed with the Cochrane Review Manager software. Treatment with TZDs decreased infarct volume and improved neurological outcome regardless of study quality, dose timing, or ischemia model (transient or permanent). Rosiglitazone and pioglitazone were similarly effective in reducing infarct volume and protecting neurologic function. Importantly, the collective data suggest that pre-treatment with a TZD is not required for neuroprotection, although additional studies are clearly needed to define the breadth of the therapeutic window. The data warrant further studies into the potential acute use of TZDs for ischemic stroke therapy in the general population.
Department of Pharmacology, University of California San Diego, San Diego, California, USA.
Amanda T
AT
White
Anne N
AN
Murphy
D000818:Animals; D002545:Brain Ischemia / Q000188:drug therapy* / Q000517:prevention & control*; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006801:Humans; D018696:Neuroprotective Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D013045:Species Specificity; D020521:Stroke / Q000188:drug therapy* / Q000517:prevention & control*; D045162:Thiazolidinediones / Q000008:administration & dosage* / Q000627:therapeutic use
D018696:Neuroprotective Agents; D045162:Thiazolidinediones